Copley 10-Q: Going Concern Persists as Trust Falls to $46.2M After 12.9M-Share Redemption
COPL is trading near its 52-week low of $10.03 (7.1% above the low) on light trading volume (0.4× avg).
Summary
Copley's Q3 10-Q keeps the going-concern warning: $110,602 of cash outside trust, a $1.42M working capital deficit, and only about $46.2M left in trust after 12.9M shares redeemed for roughly $137.1M. The Ignite deal is terminated, and each monthly extension now depends on a discretionary $200,000 sponsor deposit.
Key Events · Earnings and Guidance · COPL
-
Going Concern Doubt Reiterated
At September 30, 2026, cash stood at $110,602 against a $1,420,286 working capital deficit. Management states that mandatory liquidation at the end of the completion window raises substantial doubt about the company's ability to continue as a going concern.
-
Trust Cut to $46.2M After Redemption
Holders of 12,899,720 Class A shares redeemed at approximately $10.63 per share for roughly $137.1 million, leaving about $46.2 million in the trust account and 4,350,280 Class A shares subject to possible redemption.
-
Ignite Deal Terminated, No Replacement
The June 10, 2026 business combination agreement with Ignite Proteomics was mutually terminated on October 9, 2026, and the financing contemplated for that transaction is no longer a funding source.
-
Extensions Now Month-to-Month
Shareholders approved up to twelve one-month extensions to as late as November 2, 2027, each requiring a $200,000 sponsor deposit under a $2,400,000 promissory note. The first drawdown extended the deadline to December 2, 2026, and the sponsor is not obligated to fund further extensions.
Analysis · COPL · Real Estate & Construction
The quarter itself is uneventful: $615,436 of net income on trust interest, offset by $1,019,445 of G&A. What matters is the balance sheet behind it. Cash outside the trust stands at $110,602 against a $1,420,286 working capital deficit, and management explicitly states that mandatory liquidation at the end of the completion window raises substantial doubt about the company's ability to continue as a going concern. With the Ignite Proteomics deal terminated on October 9, the financing once intended to fund a combination is no longer available. Shareholders approved up to twelve monthly extensions to November 2, 2027, but 12,899,720 Class A shares redeemed at about $10.63 for roughly $137.1 million, leaving only about $46.2 million in trust and 4,350,280 redeemable shares. Each monthly extension costs the sponsor a $200,000 deposit, and the sponsor is not obligated to fund any of them, so the runway is now a month-to-month decision by the sponsor rather than a contractual certainty.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COPL was trading at $10.75 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $212.2M. The 52-week trading range was $10.03 to $10.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.